FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileFirst Tracks Biotherapeutics Inc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TRAX
First Tracks Biotherapeutics Inc Stock AnalysisComprehensive stock analysis for First Tracks Biotherapeutics Inc (TRAX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTRAX
TRAX
First Tracks Biotherapeutics Inc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TRAX
  1. Home
  2. Stocks
  3. First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Inc

🇺🇸TRAX•NASDAQ

First Tracks Biotherapeutics Inc

🇺🇸TRAX•NASDAQ
Market cap
$1.87B

Your view on TRAX

Mkt Cap
$1.87B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About First Tracks Biotherapeutics Inc

Industry
Biotechnology
Sector
Healthcare
CEO
Daniel R. Faga
Headquarters
10770 Wateridge Circle, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Daniel R. Faga
Headquarters
10770 Wateridge Circle, San Diego, CA, US
Description

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments.

The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for First Tracks Biotherapeutics Inc. Starting points for First Tracks Biotherapeutics Inc: EPS -$4.41, beta 3.37 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for First Tracks Biotherapeutics Inc. Trailing twelve-month EPS for First Tracks Biotherapeutics Inc stands at -$4.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$69.80average of 10 firms, last 12 months
Current price—

Buy

Targets, low to high

$69.80

Low $46.00

Middle $65.00

High $110.00

Analyst ratings

10 firms, last 12 months
  • Strong Buy0
  • Buy10
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.73−$0.76−$3.99−$3.46
Lowest estimate−$0.81−$0.88−$4.03−$3.93
Highest estimate−$0.67−$0.63−$3.97−$2.69
Number of analysts6467
A year ago—−$1.45$0.001—
Growth vs a year ago—+47.4%——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$75.00M$0.00
Lowest estimate$0.00$0.00$75.00M$0.00
Highest estimate$0.00$0.00$75.00M$0.00
Number of analysts0040
A year ago—$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for First Tracks Biotherapeutics Inc. First Tracks Biotherapeutics Inc has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold TRAX19 companies · 8 funds
Compare TRAX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACRSAclaris Therapeutics, Inc.HealthcareBiotechnology$555.1M
ANABAnaptysBio, Inc.HealthcareBiotechnology$1.4B
CLYMClimb Bio, Inc.HealthcareBiotechnology$546.3M
ELDNEledon Pharmaceuticals, Inc.HealthcareBiotechnology$171.5M
IMUXImmunic, Inc.HealthcareBiotechnology$102.6M
IMVTImmunovant, Inc.HealthcareBiotechnology$6.9B
MLTXMoonLake ImmunotherapeuticsHealthcareBiotechnology$918.3M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PHARPharming Group N.V.HealthcareNASDAQ$882.4M
PHATPhathom Pharmaceuticals, Inc.HealthcareNASDAQ$430.8M
PHGUFPharming Group N.V.HealthcareOTC$1.1B
PHIOPhio Pharmaceuticals Corp.HealthcareNASDAQ$8.6M
PHMMFPharma Mar, S.A.HealthcareOTC$1.5B
PHRM.CNPharmaTher Holdings Ltd.HealthcareCNQ$9.1M
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
PHVSPharvaris N.V.HealthcareNASDAQ$2.2B
PHYOFIXICO plcHealthcareOTC$6.5M
PKTXProtoKinetix, IncorporatedHealthcareOTC$2.7M
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$41.0M
PLRZPolyrizon Ltd.HealthcareNASDAQ$12.4M
ETFs holding First Tracks Biotherapeutics Inc
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.41%
IWMiShares Russell 2000 ETF$76.6B in assets0.05%
VXFVanguard Extended Market ETF$30.2B in assets0.02%
BBCVirtus LifeSci Biotech Clinical Trials ETF$32M in assets2.12%
OMFSInvesco Russell 2000 Dynamic Multifactor ETF$267M in assets0.63%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.07%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.05%

Largest holders first, then the funds most concentrated in TRAX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold First Tracks Biotherapeutics Inc, and how their positions are changing. At a $1.87B market value, institutional positions materially move First Tracks Biotherapeutics Inc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by First Tracks Biotherapeutics Inc executives and directors. Shares of First Tracks Biotherapeutics Inc have traded between $14.72 and $48.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for First Tracks Biotherapeutics Inc. Coverage tracks First Tracks Biotherapeutics Inc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of First Tracks Biotherapeutics Inc.

TRAX AnalysisFair
Past
5
Growth
2
Health
5
Profit
1
Value
1